Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Who are the high-risk patients and what are the best treatment options?

Current Opinion in Urology

Volumn 21, Issue 1, 2011, Pages 42-48

  Robert, Grégoire ^a,d   Descazeaud, Aurélien ^b,d   De La Taille, Alexandre ^c,d  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d INSERM   (France)

Author keywords

benign prostatic hyperplasia; medical treatment; risk factor

Indexed keywords

DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PLACEBO; TAMSULOSIN;

ALCOHOL CONSUMPTION; ARTICLE; DEPRESSION; DISEASE COURSE; HIGH RISK PATIENT; HUMAN; LOWER URINARY TRACT SYMPTOM; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY; URINE RETENTION;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-ANTAGONISTS; HUMANS; INFLAMMATION; MALE; METABOLIC SYNDROME X; PROSTATIC HYPERPLASIA; RISK FACTORS; UROLOGIC DISEASES;

EID: 78650513719     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32834100b3     Document Type: Article

References (28)

1. Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: Risk factors for acute urinary retention. J Urol 1997; 158:481-487.
2. Kok ET, Schouten BW, Bohnen AM, et al. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: The Krimpen Study. J Urol 2009; 181:710-716. Large prospective observational study investigating new kinds of risk factors for LUTS/BPH such as lifestyle parameters, medication therapies, or erectile dysfunction.
3. Crawford ED, Wilson SS, McConnell JD, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 2006; 175:1422-1426; discussion 1426-1427.
4. Slawin KM, Kattan MW, Roehrborn CG, Wilson T. Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia. Urology 2006; 67:84-88.
5. Sarma AV, Jacobson DJ, St Sauver JL, et al. Smoking and acute urinary retention: The Olmsted County study of urinary symptoms and health status among men. Prostate 2009; 69:699-705. Ten-year follow-up of the Olmsted County study reporting only 114 episodes of acute urinary retention over 2089 men.
6. Emberton M, Fitzpatrick JM, Garcia-Losa M, et al. Progression of benign prostatic hyperplasia: Systematic review of the placebo arms of clinical trials. BJU Int 2008; 102:981-986.
7. Vallancien G, Emberton M, Alcaraz A, et al. Alfuzosin 10mg once daily for treating benign prostatic hyperplasia: A 3-year experience in real-life practice. BJU Int 2008; 101:847-852.
8. Lo KL, Chan MC, Wong A, et al. Long-term outcome of patients with a successful trial without catheter, after treatment with an alpha-adrenergic receptor blocker for acute urinary retention caused by benign prostatic hyperplasia. Int Urol Nephrol 2010; 42:7-12. Retrospective study on the natural history of 246 patients with a first episode of acute urinary retention. The percentage of patients with medical treatment failure at 12 and 60 months increases from 14 to 51.
9. Kupelian V, McVary KT, Kaplan SA, et al. Association of lower urinary tract symptoms and the metabolic syndrome: Results from the Boston Area Community Health Survey. J Urol 2009; 182:616-624; discussion 624-615. Large observational study reporting an association between LUTS and the metabolic syndrome.
10. Moul S, McVary KT. Lower urinary tract symptoms, obesity and the metabolic syndrome. Curr Opin Urol 2010; 20:7-12.
11. Vikram A, Jena GB, Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats: Linking hyperinsulinemia with benign prostate hyperplasia. Prostate 2010; 70:79-89. In-vivo and in-vitro experiments confirming that hyperinsulinemic condition leads to increased cellular proliferation, enhanced alpha-adrenoceptor-mediated contraction, and enlarged prostate in rats.
12. Wong SY, Woo J, Leung JC, Leung PC. Depressive symptoms and lifestyle factors as risk factors of lower urinary tract symptoms in Southern Chinese men: A prospective study. Aging Male 2010; 13:113-119. Prospective observational study of the relationship between depressive symptoms and LUTS. Depressive symptoms and high alcohol intakes are leading to increased OR of severe LUTS.
13. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007; 51:1202-1216.
14. Robert G, Descazeaud A, Allory Y, et al. Should we investigate prostatic inflammation for the management of benign prostatic hyperplasia? Eur Urol Suppl 2009; 8:879-886.
15. Nickel JC, Roehrborn CG, O'Leary MP, et al. The relationship between prostate inflammation and lower urinary tract symptoms: Examination of baseline data from the REDUCE trial. Eur Urol 2008; 54:1379-1384.
16. Schenk JM, Kristal AR, Neuhouser ML, et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: Results from the prostate cancer prevention trial. Am J Epidemiol 2010; 171:571-582. The clinical data and blood samples collected during the PCPT study were used to investigate the link between biomarkers of inflammation and LUTS. Results suggest that systemic inflammation or lower levels of soluble receptors that bind inflammatory cytokines increase LUTS/BPH risk.
17. St Sauver JL, Sarma AV, Jacobson DJ, et al. Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort. Am J Epidemiol 2009; 169:1281-1290. The authors examined the association between CRP levels and rapid increases in prostate volume, prostate-specific antigen levels, and LUTS, as well as rapid decreases in peak flow rates. The results suggest that rapid increases in irritative LUTS and rapid decreases in peak flow rates may be due to inflammatory processes.
18. Rohrmann S, De Marzo AM, Smit E, et al. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 2005; 62:27-33. (Pubitemid 39614290)
19. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338:557-563.
20. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387-2398.
21. Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57:123-131. Prospective randomized clinical trial providing evidences of a better reduction in the risk of complication by the 5-ARI and the combination therapy compared to the alpha bloquant alone.
22. Roehrborn CG. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: Results of a 2-year placebo-controlled study. BJU Int 2006; 97:734-741.
23. Kaplan S, Garvin D, Gilhooly P, et al. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and longterm response to finasteride. The Pless Study Group. Urology 2000; 56: 610-616.
24. Masumori N, Furuya R, Tanaka Y, et al. The 12-year symptomatic outcome of transurethral resection of the prostate for patients with lower urinary tract symptoms suggestive of benign prostatic obstruction compared to the urodynamic findings before surgery. BJU Int 2010; 105:1429-1433. Retrospective study confirming that the symptomatic improvement provided by TURP lasts for more than 10 years, even if there is a gradual deterioration in time.
25. Hoekstra RJ, vanMelick HH, Kok ET, Ruud Bosch JL. A 10-year follow-up after transurethral resection of the prostate, contact laser prostatectomy and electrovaporization in men with benign prostatic hyperplasia; long-termresults of a randomized controlled trial. BJU Int 2010. Prospective randomized trial comparing the long-term functional outcome of TURP with other techniques. The authors confirm a long-term improvement in all parameters includingQmax and an actuarial failure rate of only 11% at 10-year follow-up.
26. Flanigan RC, Reda DJ, Wasson JH, et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: A Department of Veterans Affairs cooperative study. J Urol 1998; 160:12-16; discussion 16-17.
27. Descazeaud A, Robert G, Lebdai S, et al. Impact of oral anticoagulation on morbidity of transurethral resection of the prostate. World J Urol 2010. [Epub ahead of print] PMID: 20577744.
28. Lebdai S, Robert G, Devonnec M, et al. Management of patients under anticoagulants for transurethral resection of the prostate: A multicentric study by the CTMH-AFU. Prog Urol 2009; 19:553-557.